Suchergebnisse - "Immunologic Factors"

PubPharm (1.293)

1

Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis

enthalten in: Journal of neurology | 2024

von Bajrami, A. | Tamanti, A. | Peloso, A. | +8

2

Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis : A real world study

enthalten in: Clinical neurology and neurosurgery | 2024

von Alroughani, R. | Al-Hashel, J. | Ahmed, S.

3

Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8+ T-Cell Proliferation in Patients With Multiple Sclerosis

enthalten in: Neurology(R) neuroimmunology & neuroinflammation | 2024

von Abbadessa, G. | Lepore, M. | Bruzzaniti, S. | +9

4

Extended interval dosing strategies in multiple sclerosis : insights from natalizumab and ocrelizumab trials

enthalten in: Journal of neurology | 2024

von Zid, Y. | Robertson, N.

5

CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors : a phase 2 randomized trial

enthalten in: Investigational new drugs | 2024

von Armstrong, A. | Geva, R. | Chung, H. | +14

6

Serum sickness in a multiple sclerosis patient treated with ocrelizumab

enthalten in: Journal of neurology | 2024

von Mantero, V. | Cordano, C. | Balgera, R. | +3

7

The Binding of the SARS-CoV-2 Spike Protein to Platelet Factor 4 : A Proposed Mechanism for the Generation of Pathogenic Antibodies

enthalten in: Biomolecules | 2024

von Nguyen, T. | Chen, L. | Khan, N. | +4

8

COVID-19 outbreak in Italy : an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients

enthalten in: Journal of neurology | 2024

von Bisecco, A. | Matrone, F. | Capobianco, M. | +59

9

Alterations in the innate and adaptive immune system in a real-world cohort of multiple sclerosis patients treated with ocrelizumab

enthalten in: Clinical immunology (Orlando, Fla.) | 2024

von Beckers, L. | Baeten, P. | Popescu, V. | +9

10

Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity

enthalten in: Multiple sclerosis (Houndmills, Basingstoke, England) | 2024

von Bou Rjeily, N. | Fitzgerald, K. | Mowry, E.

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[130]